Amgen's Senior Vice President and Head of Research, Dave Lacey, M.D., said: "We are pleased to enter into this collaboration that takes advantage of Amgen's expertise in monoclonal antibody technology and the database that Oxford Genome Sciences has established."
OGeS' new collaboration with Amgen follows a previous agreement that the company signed with Medarex and Biosite (see press release of 18 September 2007). OGeS now has access to the two leading technologies that are used to generate fully human monoclonal antibodies as it works to develop its own product pipeline of cancer therapeutics and diagnostics.
About Oxford Genome Sciences
Oxford Genome Sciences (OGeS) is focused on the development of targeted medicines for oncology. The company uses OGAP(R), which it has developed into the world's largest cancer protein database, to discover novel clinically relevant drug targets and diagnostics.
OGeS' strategy is to use its unique and integrated OGAP(R) discovery platform in alliances with the world's leading antibody companies to develop OGeS targets into new antibody therapeutics and diagnostics that will deliver innovative and cost-effective medicines to fulfil unmet patient needs in the field of cancer. The company has signed a number of collaborations in the area of cancer, which are together designed to achieve OGeS' objective of developing novel personalised solutions to the management of cancer. Specifically in 2006, OGeS entered into partnerships with Medarex to discover, develop and commercialise new human antibody therapeutics for the treatment of cancers and with Biosite to develop a new diagnostic protein panel for relapsing colorectal cancer.
OGeS, a privately held company, was formed in 2004 and is based near Oxford, UK.
Oxford Genome Anatomy P
|SOURCE Oxford Genome Sciences|
Copyright©2007 PR Newswire.
All rights reserved